Sagimet Biosciences Enters Material Definitive Agreement
Ticker: SGMT · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1400118
Sentiment: neutral
Topics: material-definitive-agreement, filing-update
TL;DR
Sagimet Biosciences just signed a big deal, filing an 8-K on Aug 15th.
AI Summary
On August 15, 2024, Sagimet Biosciences Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as 3-V Biosciences, Inc., is headquartered in San Mateo, California.
Why It Matters
This filing indicates a significant new agreement for Sagimet Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
- 3-V Biosciences, Inc. (company) — Former company name
- San Mateo, California (location) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Sagimet Biosciences Inc. on August 15, 2024?
The filing does not specify the exact nature of the Material Definitive Agreement, only that one was entered into on August 15, 2024.
What is the primary business of Sagimet Biosciences Inc.?
Sagimet Biosciences Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
When was Sagimet Biosciences Inc. formerly known as 3-V Biosciences, Inc.?
The company changed its name from 3-V Biosciences, Inc. on May 21, 2007.
Where are Sagimet Biosciences Inc.'s principal executive offices located?
The principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the SEC file number for Sagimet Biosciences Inc.?
The SEC file number for Sagimet Biosciences Inc. is 001-41742.
Filing Stats: 803 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-08-16 16:53:50
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
- $75,000,000 — ng an aggregate offering price of up to $75,000,000. Subject to the terms and conditions o
Filing Documents
- tm2421627d3_8k.htm (8-K) — 30KB
- 0001104659-24-090546.txt ( ) — 201KB
- sgmt-20240815.xsd (EX-101.SCH) — 3KB
- sgmt-20240815_lab.xml (EX-101.LAB) — 33KB
- sgmt-20240815_pre.xml (EX-101.PRE) — 22KB
- tm2421627d3_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 10.1 Controlled Equity Offering Sales Agreement, dated as of August 15, 2024, by and between Cantor Fitzgerald & Co. and Sagimet Biosciences Inc. (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form S-3 filed on August 15, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: August 16, 2024 By: /s/ David Happel David Happel Chief Executive Officer